Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: Validation of CA 15-3 measurement in cerebrospinal fluid;Détection précoce des métastases leptomé ningées chez les patientes atteintes de cancer du sein métastatique: Validation du dosage du CA 15-3 dans le liquide céphalorachidienpp

Annales de Biologie Clinique

Volumn 65, Issue 6, 2007, Pages 653-658

  Gauchez, A S ^a,b   Pez, E ^a   Boutonnat, J ^a   Bourre, J C ^a   Pelletier, L ^b   Payan, R ^c   Mousseau, M ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c Clinique Belledonne   (France)

Author keywords

CA 15 3; CSF; Leptomeningeal metastases; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CEREBROSPINAL FLUID; FEMALE; HUMAN; MENINGIOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REPRODUCIBILITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 37049035592     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2007.0170     Document Type: Article

References (15)

1. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003 ; 21 : 25-66.
2. Gavrilovic IT, Posner JB. Brain metastases : epidemiology and pathophysiology. J Neurooncol 2005 ; 75 : 5-14.
3. Mousseau M. Chemotherapy of brain tumors : biological basis of its limited efficacy. Bull Cancer 1994 ; 81 : 414-24.
4. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004 ; 40 : 379-82.
5. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastasis after trastuzumab therapy in patients with breast carcinoma. Cancer 2004 ; 101 : 810-6.
6. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastasis in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005 ; 16 : 1772-7.
7. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006 ; 15 : 219-25.
8. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005 ; 31 : 312-8.
9. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004 ; 22 : 3608-17.
10. Grossi PM, Ochiai H, Archer GE, et al. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003 ; 9 : 5514-20.
11. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006 ; 7 : 778-80.
12. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006 ; 15 : 1373-7.
13. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005 ; 167 : 913-20.
14. Kosmas C, Tsavaris NB, Tsakonas G, et al. Cerebrospinal fluid tumour marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer. Med Sci Monit 2005 ; 11 : 398-401.
15. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumours. Nat Genet 2003 ; 33 : 49-54.